Fundraising Fox

Harmony Biosciences

NASDAQ: HRMY

Northbrook, US · Founded 2017 · Delaware corporation · 341 employees on LinkedIn · 5 known investors

Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases. The company serves patients, families, and advocates in the rare disease community through novel drug development and patient-centered approaches.

BiotechHealthtechMedical Devices

Founders & leadership

Harmony Biosciences was founded in 2017 by Jeffrey Aronin.

JA
Jeffrey AronininFounder
JM
Jeffrey M. Dayno, M.D.inPresident and Chief Executive Officer
PM
Patrick MorrisinSecretary and Treasurer
RR
Robert RepellaDirector and Chief Executive Officer
DP
Darien ParhadChief Financial Officer

Board

ARAaron Royston
Aaron Roystonin𝕏Board Of Directors2017–2020Managing Partner at venBio Partners
DA
Dr. Andreas WickiBoard director
JNJack Nielsen
Jack NielseninBoard MemberManaging Partner at Vivo Capital
AGAntonio Gracias
Antonio GraciasinBoard directorFounder, Chief Executive Officer & Chief Investment Officer at Valor Equity Partners
ME
Martin EdwardsBoard director
JSJuan Sabater
Juan SabaterBoard directorPartner and Co-President at Valor Equity Partners
WG
Wilbur Gantz IIIBoard director

Investors · 5

Aisling CapitalNew York
Paragon Biosciences LLCChicago
Valor Equity PartnersChicagovia Antonio Gracias · board
venBio PartnersSan Franciscovia Aaron Royston · board
Vivo CapitalreportedPalo Alto · $10M – $50Mvia Jack Nielsen · board

Reported raises · per SEC filings

Form D private placements

$345M disclosed across 3 rounds · 2017–2019

▶$50MraisedAug 2019 · 30 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • JACK BECH NIELSENDirector
  • MARTIN EDWARDSDirector
  • AARON ROYSTONDirector
  • DR. ANDREAS WICKIDirector
  • WILBUR GANTZ, IIIDirector
  • OCTAGON CAPITAL GROUP, LLCPromoter
  • JUAN SABATERDirector
  • JOHN JACOBSExecutive Officer, Director
  • JOHN VITTORIAExecutive Officer
  • ANDREW SERAFINExecutive Officer
  • JEFFREY ARONINDirector
  • ANTONIO GRACIASDirector
  • PATRICK MORRISExecutive Officer
Offering amount
$50M
Amount sold
$50M
Minimum investment
$14K
Sales commissions
$1M
Placement agents
OCTAGON CAPITAL GROUP, LLC
First sale
Aug 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25MraisedJan 2018 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Patrick MorrisExecutive Officer
  • Jeffrey AroninDirector
  • Aaron RoystonDirector
  • Dr. Andreas WickiDirector
  • Jack NielsenDirector
  • Robert RepellaExecutive Officer, Director
  • Antonio GraciasDirector
  • Martin EdwardsDirector
  • Juan SabaterDirector
  • Wilbur Gantz IIIDirector
  • Darien ParhadExecutive Officer
Offering amount
$25M
Amount sold
$25M
First sale
Jan 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$270MraisedOct 2017 · 29 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Patrick MorrisExecutive Officer
  • Wilbur Gantz IIIDirector
  • Octagon Capital Group, LLCPromoter
  • Darien ParhadExecutive Officer
  • Juan SabaterDirector
  • Martin EdwardsDirector
  • Aaron RoystonDirector
  • Jeffrey AroninDirector
  • Dr. Andreas WickiDirector
  • Jack Bech NielsenDirector
  • Robert RepellaDirector
  • Antonio GraciasDirector
Offering amount
$270M
Amount sold
$270M
Minimum investment
$50K
Sales commissions
$5.9M
Placement agents
Octagon Capital Group, LLC
First sale
Sep 2017
Incorporated
Limited Liability Company, Illinois, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Precision BioSciences36 shared keywordsPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

Companies competing with Harmony Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

H.C. Wainwright reiterates Harmony Biosciences stock rating on strong Q2 results By Investing.cominvesting.com · Jul 2026Harmony Biosciences reports record Q2 revenue, CFO departure By Investing.cominvesting.com · Jul 2026Harmony Biosciences Announces Preliminary Q2 Revenue, CFO Transition — Says Executive’s Departure Not Due To Any Disagreementstocktwits.com · Jul 2026Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?finance.yahoo.com · Jul 2026Is Harmony Biosciences Holdings (HRMY) A Bargain After Its Neuroscience Pipeline Push? - Simply Wall St Newssimplywall.st · Jul 2026

Frequently asked questions

What does Harmony Biosciences do?
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases. The company serves patients, families, and advocates in the rare disease community through novel drug development and patient-centered approaches.
Who founded Harmony Biosciences?
Harmony Biosciences was founded by Jeffrey Aronin in 2017.
Who are Harmony Biosciences's investors?
Harmony Biosciences's investors include Aisling Capital, Paragon Biosciences LLC, Valor Equity Partners, venBio Partners, Vivo Capital.
How much funding has Harmony Biosciences raised?
Harmony Biosciences has disclosed $345M raised across 3 rounds.
Where is Harmony Biosciences headquartered?
Harmony Biosciences is headquartered in Northbrook, US.